# Insulet Corporation (PODD) — Stock CV

Insulet Corporation is a $9.38B healthcare company. Revenue grew 29.4% over the last year, it keeps 12¢ of every dollar of sales as profit, and its net debt equals ~0.7 years of free cash flow. It trades at 25.0× earnings — near the lowest of its own history.

> Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage.

## Identity

- **Ticker**: PODD
- **Sector**: Healthcare
- **Industry**: Surgical & Medical Instruments & Apparatus
- **Headquarters**: ACTON, MA
- **Employees**: 5 400
- **Website**: https://www.insulet.com
- **Market cap**: $9.38B
- **Last price**: $135.28
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $3.05B
- **Net income**: $375M
- **Free cash flow**: $294M
- **Net debt**: $215M
- **P/E**: 25.0
- **Revenue growth (YoY)**: 29.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 69 |
| Growth | 100 |
| Profitability | 72 |
| Health | 95 |
| Quality | 82 |
| Moat | 31 |

## Qualifications (beginner checklist) — 10 of 10 passed

- [x] Revenue growing — +29.4% YoY
- [x] Profitable — $375M TTM
- [x] Profit growing — +273.8% YoY
- [x] Generates cash — $294M TTM
- [x] Debt under control — ~0.7y of cash flow to repay
- [x] Established company — $9.38B market cap
- [x] Not printing shares — +9.0% shares over ~5y
- [x] Proven track record — 8/10 profitable years
- [x] Financially stable — Altman Z 4.6 — safe
- [x] Valuation not extreme — P/E 25.0

## Experience (career milestones)

- **Q2 2026** — 2 open-market insider purchases: ~6K shares bought by insiders
- **FY2024** — Best year on record: $418M net income
- **FY2021** — Revenue crossed $1B: $1.10B for the year
- **FY2018** — Turned profitable: $3.29M net income after a loss year
- **1978** — Between 1978 and 1988, Robert Channon, working with Guy's Hospital and the Bristol Royal Infirmary, developed a…
- **1976** — The first commercialized insulin pump was created and was named the Biostator

## Strengths

- High gross margin (71.1%)
- Revenue growing 29.4% year over year
- Could repay net debt from ~1.4 years of free cash flow
- Interest covered 33.6× by operating earnings
- Piotroski F-Score 7/9 — fundamentally strong checklist

## Watch-outs

- Loss-making in 2 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $1.10B | $16.8M | -$180M |
| FY2022 | $1.31B | $4.60M | -$3.90M |
| FY2023 | $1.70B | $206M | $70.1M |
| FY2024 | $2.07B | $418M | $305M |
| FY2025 | $2.71B | $247M | $378M |

---

Source: https://stockcv.com/PODD — derived from company filings; may be delayed or incomplete. Information, not investment advice.